Location History:
- Acton, CA (1996 - 1998)
- St. Rosemere, CA (1999)
Company Filing History:
2 out of 64 
1 out of 16 
1 out of 1 Years Active: 1996-1999
Title: Innovations and Contributions of Inventor Robert A. Kirby
Introduction
Robert A. Kirby, an esteemed inventor based in Acton, California, has made significant contributions to the field of biopharmaceuticals. With a portfolio that includes five patents, Kirby’s innovative work primarily focuses on radionuclide chelating compounds and dopamine receptor affinity compounds. His inventions have promising applications in both diagnostic and therapeutic realms.
Latest Patents
Among Kirby’s latest patents is the development of hydrazino-type N₂S₂ radionuclide chelating compounds. These compounds are designed for conjugation to targeting molecules such as proteins, peptides, or antibodies, facilitating the creation of labeled targeting molecules for use in diagnosis and therapy. Additionally, he has patented benzyl-substituted compounds that exhibit dopamine receptor affinity, specifically targeting D4 receptor-selective compounds. These compounds are characterized by a general formula involving saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings, showcasing Kirby's innovative approach to pharmacology.
Career Highlights
Throughout his career, Robert A. Kirby has demonstrated expertise in the biopharmaceutical industry, having worked with notable companies such as Allelix Biopharmaceuticals Inc. and Resolution Pharmaceuticals Inc. His roles in these organizations allowed him to push the boundaries of medical research and innovation.
Collaborations
In his pursuit of groundbreaking inventions, Kirby collaborated with distinguished colleagues, including Alfred Pollak and Robert Dunn-Dufault. These partnerships reflect his commitment to teamwork and shared efforts in advancing healthcare solutions.
Conclusion
Robert A. Kirby exemplifies the spirit of innovation in the biopharmaceutical sector. His five patents serve as a testament to his creative prowess and dedication to improving medical diagnostics and therapies. As his work continues to evolve, his contributions are poised to make a lasting impact on the industry.